On Thursday, Tilly’s Inc (NYSE:TLYS)’s shares declined -24.77% to $9.78.
Tilly’s Inc (TLYS) declared financial results for the first quarter of fiscal 2015 ended May 2, 2015.
For the first quarter ended May 2, 2015:
- Total net sales were $120.2 million, an enhance of 8.1% contrast to $111.1 million in the first quarter of 2014.
- Comparable store sales, which comprise e-commerce sales, raised 2.0% contrast to the same 13-week period in 2014.
- Gross profit raised 15.3% to $36.1 million contrast to $31.3 million in the first quarter of 2014. Gross margin was 30.0% contrast to 28.2% in the first quarter of 2014. The 180 basis point enhance in gross margin was primarily due to a 90 basis point enhance in product margins and lower buying, distribution and occupancy costs as a percentage of net sales due to positive comparable store sales, and a favorable rent adjustment related to prior years.
- Operating income was $2.1 million, contrast to operating income of $1.1 million in the first quarter of 2014.
- Net income was $1.3 million, or $0.05 per diluted share, based on a weighted average diluted share count of 28.3 million shares and an effective tax rate of about 40%. This compares to net income in the first quarter of 2014 of $0.6 million, or $0.02 per diluted share, based on a weighted average diluted share count of 28.2 million shares and an effective tax rate of about 45%, reflecting a discrete item related to stock option forfeitures.
Tilly’s, Inc. retails casual clothing, footwear, and accessories for teens and young adults in the United States. Its apparel merchandise comprises tops, outerwear, bottoms, and dresses; and accessories merchandise comprises backpacks, hats, sunglasses, headphones, handbags, watches, jewelry, and others.
NeoStem Inc (NASDAQ:NBS)’s shares dropped -21.67% to $2.06.
NeoStem Inc (NBS) declared the pricing of an underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. The gross proceeds to NeoStem from this offering are predictable to be $25,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company has granted the underwriter a 45-day option to purchase up to an aggregate of 1,875,000 additional shares of its common stock to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital, counting research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, planned transactions and other general corporate purposes. The offering is predictable to close on or about June 2, 2015, subject to the satisfaction of customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
NeoStem, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes.
At the end of Thursday’s trade, IMRIS Inc (NASDAQ:IMRS)‘s shares dipped -19.35% to $0.0500.
IMRIS Inc (IMRS) declared that the Company, its partner NeuroArm Surgical Ltd., and its U.S. partner, IMRIS, Inc. have each filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
As part of the filing, IMRIS declared that subject to a marketing process and Court approval, it intends to sell its business operations to an associate of Deerfield Administration Company, L.P. (“Deerfield”). In addition, the Company has secured a commitment for debtor-in-possession financing from Deerfield, which, in addition to IMRIS’s ongoing cash flow, will ensure it is able to continue meeting its financial obligations throughout the Chapter 11 case. During this time, IMRIS intends to conduct a marketing process for its operating businesses.
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment.
RXi Pharmaceuticals Corp (NASDAQ:RXII), ended its Thursday’s trading session with -16.48% loss, and closed at $0.380.
RXi Pharmaceuticals Corp (RXII) declared the pricing of a public offering of 26 million units at a price to the public of $0.40 per share for gross proceeds of about $10.4 million. Each unit comprises of (i) one share of common stock, (ii) a 13-month overallotment purchase right to purchase 0.50 of a share of common stock at a price of $0.455 per share and (iii) a five-year warrant to purchase 0.50 of a share of common stock at a price of $0.52 per share. The shares of common stock, overallotment purchase rights and warrants are right away separable and will be issued separately. Net proceeds, after estimated placement agent fees and other estimated offering expenses, and assuming the overallotment purchase rights and warrants are not exercised, will be about $9.3 million. The offering is predictable to close on or about June 2, 2015, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co., LLC is acting as the Company’s exclusive placement agent on a best efforts basis with respect to the offering.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
